Edwards Lifesciences Corporation (NYSE: EW) is ranked among the best medical device stocks to invest in. Piper Sandler maintains an Overweight rating and $90 price target ahead of the 7-year findings from Edwards’ PARTNER 3 study, set to be presented on October 27 at the TCT conference.

The historic PARTNER 3 trial by Edwards compares surgical aortic valve replacement (SAVR) with its Sapien 3 transcatheter aortic valve replacement (TAVR) in low-risk patients over a ten-year follow-up period.

Piper Sandler predicts that upcoming data will show TAVR is not inferior to SAVR, potentially making the findings a “non-event with minimal commercial implications.” Edwards Lifesciences Corporation develops and sells patient-focused medical innovations for the treatment of structural heart disease and critical care.

While acknowledging Edwards’ investment potential, some believe certain AI stocks offer greater upside and less downside risk. For those interested in an undervalued AI stock benefiting from tariffs and onshoring trends, a free report on the best short-term AI stock is available.

Disclosure: None. This article was originally published on Insider Monkey.

Read more at Yahoo Finance: Piper Sandler Maintains Overweight on Edwards Lifesciences (EW) Ahead of PARTNER 3 7-Year Results